Antibodies, Bispecific / immunology ; Antibodies, Bispecific / therapeutic use* ; Antineoplastic Agents, Immunological / therapeutic use ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Immune Checkpoint Inhibitors / therapeutic use ; Neoplasms / immunology* ; Neoplasms / therapy* ; Randomized Controlled Trials as Topic
Keywords
Bispecific antibodies ; Cancer
Abstract
The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.